Cencora, Inc. (COR) Stock Price & Analysis
Cencora, Inc. (COR) rose 1.58% to USD 309.89 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
COR last closed at USD 305.06; the session ranged USD 304.34–310.3 on volume of 833,375 shares. Market capitalization is $60.29B, with a 52-week range of USD 244.82–377.54 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 309.89 |
|---|---|
| Change | ▲ 1.58% (up) |
| Previous Close | USD 305.06 |
| Open | USD 306.9 |
| Day Range | USD 304.34 – 310.3 |
| 52-Week Range | USD 244.82 – 377.54 |
| Volume | 833,375 shares |
| Market Cap | $60.29B |
| Exchange | NYQ |
Technical Analysis (COR)
Nexqual's technical model rates COR "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.28 (neutral) |
| vs SMA50 | Above (USD 283.05) |
| MACD | 6 (positive) |
Analyst Ratings (COR)
Wall Street analysts rate COR "Buy" based on 12 analysts, with a mean price target of USD 355.83 (range USD 310–412), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 355.83 |
| High Target | USD 412 |
| Low Target | USD 310 |
| Buy / Hold / Sell | 12 / 2 / 0 |
Earnings (COR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 4.35 |
| Revenue Estimate | $84.15B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.75 vs est 4.73 ▲ beat |
| 2025-12-31 | USD 4.08 vs est 4.04 ▲ beat |
| 2025-09-30 | USD 3.84 vs est 3.79 ▲ beat |
| 2025-06-30 | USD 4 vs est 3.84 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (COR)
| Total Revenue | $328.68B |
|---|---|
| Revenue Growth (YoY) | +3.80% |
| Gross Margin | +3.80% |
| Operating Margin | +1.72% |
| Profit Margin | +0.78% |
| ROE | +107.13% |
| Debt / Equity | 420.99 |
| Current Ratio | 0.95 |
| Total Cash | $2.18B |
| Total Debt | $15.09B |
| Free Cash Flow | $-318.25M |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (COR)
Nexqual rates Cencora, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 2% |
| Balance Sheet | Critical — $2.18B cash vs $15.1B debt |
| Cash Flow | Weak — FCF negative: -$318M, burning cash |
| Efficiency | Strong — ROE 107%, ROA 3.5% |
Ownership (COR)
| Insider Ownership | +4.23% |
|---|---|
| Institutional Ownership | +99.10% |
| Shares Outstanding | 194.56M |
| Float | 184.00M |
| Short % of Float | +3.21% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (COR)
Cencora, Inc. is led by Robert P. Mauch Ph.D., PharmD (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:12 UTC.
| President, CEO & Director | Robert P. Mauch Ph.D., PharmD (age 58) |
|---|---|
| Executive VP & CFO | Eva C. Boratto (age 58) |
Major Backers & Investors (COR)
Notable institutional backers of Cencora, Inc. include Price (T.Rowe) Associates Inc, T. Rowe Price, FMR, LLC, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 4.75% |
| T. Rowe Price | 4.66% |
| FMR, LLC | 3.44% |
| JPMorgan | 2.51% |
| Wellington Management | 2.34% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.03% |
| BlackRock | 11.57% |
| State Street | 5.93% |
| Geode Capital | 2.86% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Cencora, Inc.'s Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
- Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DLR | Digital Realty Trust, Inc. | USD 199.08 | ▲ 11.59% |
| EQIX | Equinix, Inc. | USD 1,084.24 | ▲ 5.39% |
| EXR | Extra Space Storage Inc | USD 147.71 | ▲ 1.83% |
| CPT | Camden Property Trust | USD 113.73 | ▲ 1.54% |
| ARE | Alexandria Real Estate Equities | USD 50.94 | ▲ 2.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.